MULTIPLE MYELOMA

This study tests whether adding a drug called NT-I7 to standard CAR-T cell therapy can help the immune cells stay active longer in people with multiple myeloma that has come back or not responded to treatment. About 52 participants will receive either NT-I7 or a placebo after the…

This early-stage study tests a new drug called SHR-3836 in 99 adults with multiple myeloma that has come back or not responded to other treatments. The main goal is to find a safe dose and check for side effects. Researchers will also watch for signs that the drug is shrinking th…

This study compares a four-drug combination (Isa-VRD) against the standard three-drug regimen (VRD) in people newly diagnosed with a high-risk form of multiple myeloma who cannot have a stem cell transplant. The goal is to see if adding isatuximab helps eliminate more cancer cell…

This study compares two drug combinations for people newly diagnosed with multiple myeloma who are not eligible for or choose not to have a stem cell transplant. One group gets a new drug called elranatamab plus standard chemotherapy, while the other gets the standard drug daratu…

This study tests whether adding thiotepa to the standard chemo drug melphalan before a stem cell transplant can lower the chance of cancer returning in people with multiple myeloma. It includes 204 adults aged 18-70 who have not achieved complete remission despite prior treatment…

This study tests whether using special dosing guidelines for people with the Duffy null blood type can reduce or delay the need to lower or pause their cancer drugs, and lower the risk of fever from low white blood cells. It includes 90 adults with multiple myeloma or triple-nega…

This study tests a new drug, TQB2934, in 260 adults with multiple myeloma that has returned or stopped responding to therapy. Participants are randomly assigned to receive either TQB2934 or a standard treatment chosen by their doctor. The main goal is to see if TQB2934 can delay …

This study is for people newly diagnosed with multiple myeloma that has a specific genetic marker (+1q), which can make the disease harder to treat. Researchers will use a special scoring system to assign each person a treatment plan that matches their risk level. The goal is to …

This study tests a new treatment called BCMA-GPRC5D CAR-T for people with multiple myeloma that has returned or not responded to at least three prior therapies. The goal is to see if this therapy is safe and can help control the disease. About 28 participants aged 18 to 75 will b…

This trial tests two approved drugs, dabrafenib and trametinib, in people with rare cancers that have a BRAF V600 mutation. The drugs are already used for melanoma and lung cancer. About 30 adults, children, and teens will take part. The goal is to see if the drugs shrink tumors …

This early-phase study tests a new drug, BL-M24D1, in about 33 adults with multiple myeloma or other blood cancers that came back or didn't respond to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shows any signs of working. Par…

This study tests a new drug, IBI3003, in people with multiple myeloma whose cancer has returned or stopped responding to other treatments. The goal is to find the safest and most effective dose and see how well it controls the disease. About 360 adults will take part in this earl…

This study tests whether giving the drug daratumumab less often (every 8 weeks, then every 16 weeks) along with lenalidomide is as effective as the standard every-4-week schedule for people with multiple myeloma after a stem cell transplant. The goal is to reduce treatment burden…

This study looks at how well a drug called melflufen works in everyday medical practice for people with multiple myeloma that has come back or stopped responding to other treatments. About 50 participants will receive melflufen plus dexamethasone, and researchers will track how m…

This study tests a drug called CM336 (a BCMA/CD3 bispecific antibody) as maintenance therapy after a stem cell transplant in people newly diagnosed with multiple myeloma. The goal is to turn minimal residual disease (MRD) from positive to negative, meaning no detectable cancer ce…

This phase 3 trial tests whether a new drug combination (belantamab mafodotin plus standard drugs) works better than the current standard (daratumumab plus standard drugs) for people newly diagnosed with multiple myeloma who cannot have a bone marrow transplant. The study will en…

This study tests whether a new drug called cevostamab, combined with two standard drugs (pomalidomide and dexamethasone), works better than usual treatments for people with multiple myeloma who have already tried 1 to 3 prior therapies. About 380 adults will take part. The goal i…

This phase 3 study tests whether a new drug, JNJ-79635322, works better than the current treatment teclistamab for people with multiple myeloma that has come back or stopped responding to prior therapies. About 700 adults who have already tried 1 to 3 treatments, including specif…

This early-phase study tests a new CAR-T cell therapy called UF-KURE-BCMA for people with multiple myeloma that has come back or not responded to at least three prior treatments. The therapy uses a person's own immune cells, which are modified in a shorter process than standard C…

This early-stage trial tests a new approach for people with high-risk multiple myeloma, including those whose cancer has returned or not responded to treatment. Participants receive a radioactive antibody that seeks out and kills myeloma cells, followed by chemotherapy, radiation…

This study is testing an experimental drug called linvoseltamab for people with multiple myeloma whose cancer has returned after receiving a specific type of CAR-T cell therapy. The trial aims to see if this new treatment can help control the disease and is safe for these patient…

This study will test a new type of PET/CT scan that uses a special tracer (68Ga-BCMA) to find active multiple myeloma lesions throughout the body. The goal is to see if this scan can accurately detect the disease compared to standard biopsy. About 300 people with suspected or kno…

This study looks at whether adding a simple, home-based breathing routine to a standard exercise program can reduce bothersome symptoms like pain or fatigue in people with multiple myeloma. About 32 adults currently on a specific treatment will take part in a 6-week program. Rese…

This study tests whether taking fish oil by mouth can prevent or lessen peripheral neuropathy—a common, painful nerve damage side effect—in people receiving the chemotherapy drug bortezomib for multiple myeloma. Researchers will enroll 200 adults who have not yet started bortezom…

This study tests a program called FOCUS, delivered through a smartphone app and telemedicine, to help people with advanced cancer manage common symptoms like trouble sleeping, worry, sadness, and fatigue. The goal is to improve quality of life and make these skills accessible to …

This study is for adults with blood cancers like multiple myeloma or Waldenstrom macroglobulinaemia. It compares different treatment doses to see which works best and has the fewest side effects. The goal is to improve survival and quality of life by finding the optimal dose for …

This study looks at whether a special exercise program can help older adults who have survived blood cancers like leukemia or lymphoma age more slowly. Researchers want to find out how much and what type of exercise works best. About 180 people aged 50 and older will take part, a…

This study tests a small patch called TempTraq that continuously monitors body temperature in cancer patients receiving immunotherapy. The goal is to see if catching fevers early can prevent severe cytokine release syndrome (CRS), a serious side effect. About 136 adults staying a…

This early-stage study tests a new drug called QL2109 in 102 healthy Chinese men to see if it behaves like the approved drug Darzalex. The goal is to compare how the body processes each drug and check for side effects. This is a first step before testing in patients with multiple…